Welcome to our dedicated page for Shattuck Labs news (Ticker: STTK), a resource for investors and traders seeking the latest updates and insights on Shattuck Labs stock.
Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company that regularly issues news updates about its progress in developing therapies for autoimmune, inflammatory, and other immune-mediated diseases. The company’s announcements frequently focus on its lead program, SL-325, a potentially first-in-class Death Receptor 3 (DR3) blocking antibody designed to target the clinically validated DR3/TL1A pathway in inflammatory bowel disease (IBD) and related conditions.
News about Shattuck often covers key clinical and regulatory milestones for SL-325, including Investigational New Drug (IND) submissions, IND clearance, initiation of Phase 1 clinical trials in healthy volunteers, and dosing of the first participants. The company also reports on preclinical data for SL-325, such as high-affinity binding to DR3, potent inhibition of TL1A binding, and favorable safety and receptor occupancy findings in non-human primate studies.
Investors following STTK can also expect updates on Shattuck’s broader DR3-focused pipeline, including multiple preclinical DR3-based bispecific antibodies designed to inhibit both the DR3/TL1A axis and another biologically relevant target for IBD. Financing news is another recurring theme, with press releases detailing private placements, expected use of proceeds to advance SL-325 through Phase 1 and planned Phase 2 trials, and the company’s views on its cash runway.
Additional news items highlight Shattuck’s participation in medical and investor conferences, key opinion leader panels on DR3/TL1A biology and IBD, and changes to its Board of Directors associated with major financings. For readers tracking STTK, this page provides a centralized view of Shattuck’s clinical progress, scientific presentations, capital-raising activities, and governance developments as disclosed in its public communications.
Shattuck Labs (NASDAQ: STTK) has secured an oversubscribed private placement expected to raise up to $103 million in gross proceeds. The financing includes initial proceeds of $46 million and potential additional proceeds of $57 million from warrant exercises.
The private placement, led by OrbiMed, involves issuing 15.2M shares of common stock and pre-funded warrants for 37.4M shares at $0.8677 per share, with accompanying warrants for 52.6M shares at $1.0846 exercise price. The proceeds will fund the clinical development of SL-325, a first-in-class DR3 blocking antibody for inflammatory bowel disease treatment, through multiple Phase 2 trials.
The financing is contingent upon IND clearance for SL-325, with the combined proceeds expected to fund operations into 2029.
Shattuck Labs (NASDAQ: STTK), a biotechnology company focused on developing novel therapeutics for inflammatory and immune-related diseases, has announced its participation in the upcoming Leerink Partners Therapeutics Forum. The company's CEO, Dr. Taylor Schreiber, will participate in a panel discussion focused on DR3/TL1A and IBD on July 8, 2025.
The presentation, titled "TL1A: Pioneering a New MOA in IBD and Beyond," will take place at 4:15-5:00 PM ET at the Boston Harbor Hotel. Management will also be available for one-on-one meetings during the conference on July 8-9, 2025.
Shattuck Labs (NASDAQ: STTK), a biotechnology company focused on developing novel therapeutics targeting TNF superfamily receptors for inflammatory and immune-related diseases, has announced its participation in the upcoming 24th Annual Needham Virtual Healthcare Conference.
The company's CEO, Taylor Schreiber, M.D., Ph.D., will deliver a presentation on April 9, 2025, at 3:00 PM EDT and participate in one-on-one meetings during the conference, which runs from April 7-10, 2025. A live webcast of the presentation will be accessible through the company's website, with a replay available for up to 30 days afterward.
Shattuck Labs (NASDAQ: STTK) reported its Q4 and full-year 2024 financial results, highlighting the advancement of SL-325, a potential first-in-class DR3 blocking antibody for inflammatory bowel diseases (IBD). The company presented favorable preclinical data at ECCO 2025, demonstrating safety and full receptor occupancy.
Key financial metrics include:
- Cash position of $73.0 million as of December 31, 2024
- Q4 2024 net loss of $18.7 million ($0.37 per share)
- Full-year 2024 net loss of $75.4 million ($1.49 per share)
- R&D expenses decreased to $67.2 million in 2024 from $74.3 million in 2023
The company terminated its SL-172154 program and is now focused on SL-325, with an IND filing expected in Q3 2025. Current cash runway is expected to fund operations into 2027.
Shattuck Labs (NASDAQ: STTK) announced positive preclinical data from an IND-enabling GLP toxicology study of SL-325, their DR3 blocking antibody for inflammatory bowel disease (IBD) treatment. The study, presented at the 20th Congress of ECCO, demonstrated that SL-325 was well-tolerated in non-human primates with no evidence of toxicity or residual agonism.
The study evaluated safety, pharmacokinetics, pharmacodynamics, and immunogenicity over a 4-week dosing period followed by a 4-week recovery period. Three doses (1, 10, and 100 mg/kg) were administered intravenously, showing full and durable DR3 receptor occupancy at all dose levels. No adverse effects, infusion-related reactions, or organ dysfunction were observed, even at the highest dose of 100 mg/kg.
The company expects to file an IND in Q3 2025, with projected human dosing at 1 mg/kg Q2W through Q4W maintenance and 3 mg/kg Q2W through Q8W maintenance.
Shattuck Labs (NASDAQ: STTK) announced an upcoming oral presentation at the 20th Congress of ECCO in Inflammatory Bowel Diseases 2025, taking place in Berlin from February 19-22, 2025. The presentation will showcase results from IND-enabling toxicology studies of SL-325, their first-in-class DR3 blocking antibody, conducted in non-human primates.
Dr. Taylor Schreiber, CEO of Shattuck, will deliver the digital oral presentation titled 'Pre-Clinical Development of SL-325, a High Affinity DR3 Blocking Antibody, for Durable Blockade of the DR3/TL1A Axis in Inflammatory Bowel Disease' on February 20, 2025, at 6:15 PM CET. The presentation materials will be made available on the company's website after the event.
Shattuck Labs (NASDAQ: STTK) has announced an upcoming poster presentation at the 2025 Crohn's and Colitis Congress in San Francisco, California, scheduled for February 6-8, 2025. The presentation will focus on SL-325, a DR3-targeted, antagonistic antibody developed for the treatment of IBD.
The poster will be presented by Dr. Suresh de Silva, Shattuck's Co-Chief Scientific Officer, on Friday, February 7, 2025, from 5:00 PM to 6:30 PM PST at the Congress Exhibit Hall in The Moscone Center. The presentation materials will be made available on the company's website in the Events and Presentations section after the event.
Shattuck Labs (NASDAQ: STTK), a biotechnology company focused on developing therapeutics targeting TNF superfamily receptors for inflammatory and immune-related diseases, announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The event will take place in San Francisco from January 13-16, 2025.
Dr. Taylor Schreiber, CEO of Shattuck, will deliver a corporate update presentation on January 16, 2025, at 7:30 a.m. PT at The Westin St. Francis in the Elizabethan B room. The presentation will be available via live webcast on the company's website, with a replay accessible for up to 30 days afterward.
Shattuck Labs (NASDAQ: STTK) provided a corporate update highlighting key milestones for 2025, focusing on their DR3 blocking antibody program, SL-325. The company plans to present preclinical data at upcoming scientific conferences and expects several significant developments, including:
- GLP toxicology study data readout in Q1 2025
- IND filing in Q3 2025
- Phase 1 clinical trial initiation in Q3 2025
- DR3 bispecific development candidate nomination in H2 2025
The company reports a strong financial position with $90.1 million in cash, cash equivalents, and investments as of September 30, 2024, which is expected to fund operations into 2027. Management expressed optimism about SL-325's potential to achieve complete blockade of the DR3/TL1A signaling pathway based on non-human primate studies.